Page last updated: 2024-10-31
moxisylyte and Cataract, Membranous
moxisylyte has been researched along with Cataract, Membranous in 1 studies
Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " Pupils were dilated with phenylephrine alone for cataract identification because there were concerns that patient discomfort, due to cycloplegia occurring with the usual dilating agents of tropicamide and phenylephrine, may influence future compliance in an associated intervention study." | 3.70 | Comparative pupil dilation using phenylephrine alone or in combination with tropicamide. ( Battistutta, D; Eyeson-Annan, ML; Green, A; Hirst, LW, 1998) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Eyeson-Annan, ML | 1 |
| Hirst, LW | 1 |
| Battistutta, D | 1 |
| Green, A | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Evaluation of Light Sensitivity and Visual Acuity Changes as Consequence of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris[NCT04040790] | | 10 participants (Actual) | Interventional | 2019-09-16 | Terminated (stopped due to Several reasons: Financing ended before all study assessments were performed, covid-19 delayed design, production and shipment of IMD, experience gained during the study made it clear that lens design should be changed) |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Other Studies
1 other study available for moxisylyte and Cataract, Membranous